Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06477926 · ClinicalTrials.gov registry record · Phase 1
A Study to Assess Relative Bioavailability and Food Effect of ABBV-668 Extended-Release Formulations in Adult Participants
A Phase 1 study, sponsored by AbbVie.
- Completed
- Registry status
- Phase 1
- Development phase
- 25
- Enrollment target
NCT06477926 is a Phase 1 study that has completed, run by AbbVie. The registered enrollment target is 25 participants.
The verdict
NCT06477926, a Phase 1 study, has completed, sponsored by AbbVie.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 25 participants
- Enrollment target
Study Summary
The objectives of this study are to assess safety and tolerability of the new ABBV-668 ER tablets, to assess the oral bioavailability of the ABBV-668 ER tablets relative to the ABBV-668 IR capsules, and to assess the pharmacokinetics of the ER tablets under fasting and fed conditions in healthy adults.
Interventions
- DRUG ABBV-668 IR
- DRUG ABBV-668 ER
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2024-07-09 |
| Est. Completion | 2024-09-20 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06477926
The ClinicalTrials.gov registry entry for NCT06477926 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which ABBV-668 IR is the first listed.
NCT06477926 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06477926 about?
NCT06477926 is a clinical study titled "A Study to Assess Relative Bioavailability and Food Effect of ABBV-668 Extended-Release Formulations in Adult Participants". The objectives of this study are to assess safety and tolerability of the new ABBV-668 ER tablets, to assess the oral bioavailability of the ABBV-668 ER tablets relative to the ABBV-668 IR capsules, and to assess the pharmacokinetics of the ER tablets under fasting and fed conditions in healthy adul...
What is the current status of trial NCT06477926?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 25 participants. The study started on 2024-07-09. Estimated completion is 2024-09-20.
What interventions are being tested in trial NCT06477926?
The interventions under investigation include: ABBV-668 IR (DRUG), ABBV-668 ER (DRUG).
Who is sponsoring clinical trial NCT06477926?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.